Urology News and Research

Latest Urology News and Research

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Study links poor semen quality to higher risk of various health conditions

A study of more than 9,000 men with fertility problems has revealed a correlation between the number of different defects in a man's semen and the likelihood that the man has other health problems.

6 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital.

4 Dec 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects.

2 Dec 2014

Sanovas's endoscopic imaging platform recognized by Frost & Sullivan

Based on its recent analysis of the endoscopic imaging market, Frost & Sullivan recognizes Sanovas Inc. with the 2014 Global Frost & Sullivan Award for New Product Innovation Leadership. In a market where spiralling healthcare costs impact the entire spectrum of stakeholders, Sanovas's ground-breaking endoscopic platform, MicroCam, provides the functionality of a high-end, flexible endoscope without the accompanying cost and maintenance burden.

1 Dec 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.

27 Nov 2014

Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

The U.S. Department of Agriculture (USDA) Rural Development awards Good Samaritan Hospital, a prominent downtown Los Angeles hospital, a $417,560 grant to implement a telemedicine program that will connect members of the medical staff at Good Samaritan Hospital with public health and primary care providers and their patients at six Public Health sites on the island of Guam.

27 Nov 2014

Minimally invasive surgeries successfully performed at Policlinico Gemelli in Rome with ALF-X system

It's called ALF-X and it's the innovative robotic surgical system being used by gynaecological surgeons at the A. Gemelli University Polyclinic in Rome, which has been in operation in the surgical field for a year in the Department for the Protection of Health of Women, Newborns, Children and Adolescents, directed by professor Giovanni Scambia.

26 Nov 2014

Perc NGage® and Perc NCompass® nitinol stone extractors launched by Cook Medical

Urologists now have new options for stone extraction devices when performing percutaneous nephrolithotomy (PCNL), as Cook Medical is launching the Perc NGage® and Perc NCompass® nitinol stone extractors today. The new products complement the Perc NCircle®, which has been on the market since 2002 and was the first nitinol extraction device for percutaneous procedures. Cook Medical was the first company to incorporate nitinol into its stone extraction devices.

From COOK MEDICAL INC. 26 Nov 2014

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data.

25 Nov 2014

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

20th annual edition of NCCN Guidelines for Prostate Cancer published

The National Comprehensive Cancer Network has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer—one of the eight original NCCN Guidelines published in November 1996.

23 Nov 2014

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014.

20 Nov 2014

UT Southwestern researchers identify new gene mutations involved in certain kidney cancers

Using next generation gene sequencing techniques, cancer researchers at UT Southwestern Medical Center have identified more than 3,000 new mutations involved in certain kidney cancers, findings that help explain the diversity of cancer behaviors.

17 Nov 2014

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients.

17 Nov 2014

Urology News and Research

Latest Urology News and Research

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Study links poor semen quality to higher risk of various health conditions

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Sanovas's endoscopic imaging platform recognized by Frost & Sullivan

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

Immune-suppressing protein may predict how patients respond to treatment

Good Samaritan Hospital receives $417,560 grant to implement telemedicine program

Minimally invasive surgeries successfully performed at Policlinico Gemelli in Rome with ALF-X system

Perc NGage® and Perc NCompass® nitinol stone extractors launched by Cook Medical

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

20th annual edition of NCCN Guidelines for Prostate Cancer published

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

UT Southwestern researchers identify new gene mutations involved in certain kidney cancers

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Exposure to tobacco smoke, roadway air pollution can contribute to obesity

UT Arlington professor uses tissue-engineered artificial lymph nodes to draw prostate cancer cells

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Urology News and Research

Latest Urology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in